Hengrui: rapid start of pd-1 + apatinib international multi-center stage iii liver cancer;Domestic pd-1 review completed
The shr-1210 review has been completed.Who will be the third homegrown pd-1 remains to be seen...
Hengrui: pd-1 + apatinib international multi-center stage iii liver cancer was officially launched!
2. Hengrui announced on December 22 2018.
Recently, jiangsu Hengrui pharmaceutical co., LTD. (hereinafter referred to as the "Hengrui pharmaceutical" or the "company") have company of PD antibody SHR - 1210-1 joint mesylate path, first-line treatment for hepatocellular carcinoma (HCC) international multicenter phase III clinical trials and the United States food and drug administration (hereinafter referred to as the "FDA"), the test will be carried out in the us, Europe and China synchronization.FDA tumor department led by Dr PatriciaKeegan panels and hengrui pharmaceutical medicine, through communication, head of Ⅲ period clinical trial scheme of the overall design, the selection of patients, the primary end point, the secondary end point, efficacy evaluation, statistical analysis method and relevant details set the consensus was reached, the FDA agreed and Ⅲ stage of clinical trials conducted in progression-free surial interim analysis results reaches preset statistical standard declaration for production in advance.
And disclosure: mesylate apatinib sales of about 1.3 billion yuan.So far, the company has spent about 345 million yuan on research and development related projects.
